Melanoma Research Alliance and Inspire Launch Online Community Focused on Research and Clinical Trials

WASHINGTON–(BUSINESS WIRE)–The Melanoma Research Alliance (“MRA”), the largest non-profit funder of melanoma research, in partnership with Inspire, the leading US health care social network, today announced the launch of Melanoma > Exchange, an online support community for anyone touched by melanoma to find support, ask questions and build community.

Cancer Immunotherapy IMCgp100 Shows Early Positive Results in Advanced Uveal Melanoma

Immunocore presented data showing that its leading investigational immunotherapy, IMCgp100, leads to durable tumor responses and strong survival rates in patients with advanced uveal melanoma, following two Phase 1 clinical trials.

Dr. Postow on Entrectinib in Melanoma

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of entrectinib for patients with NTRK fusion-positive melanoma.

ctDNA Predicted Early Relapse in Resected Stage II/III Melanoma

Levels of circulating tumor DNA (ctDNA) predicted worse outcomes including relapse and survival in patients with resected stage II/III melanoma, according to the results of a study published in Annals of Oncology.

Cancer in the News

Feature Articles

Biotech Unicorn’s T-Cell Receptor Therapy “Nearly Doubles” Survival in Uveal Melanoma

Immunocore, one of the only three European biotech unicorns, has presented Phase I results for its TCR immunotherapy IMCgp100 in patients suffering from metastatic uveal melanoma.

Read the full story

Posted in Melanoma In The News, Clinical Trials

New genetic mutations discovered in conjunctival melanoma

Researchers writing in JAMA Ophthalmology say that whole exome sequencing might enable the detection of molecular mutations “targetable” by cancer therapies for conjunctival melanoma, an ocular cancer with few treatment options.

Read the full story

Posted in Melanoma In The News, Other Melanoma Research

Immunotherapy Combination Improves Melanoma Outcomes, But At A Cost

Pre-surgical (neoadjuvant) treatment with the immunotherapy combination Opdivo (nivolumab) plus Yervoy (ipilimumab) nearly tripled objective response rates (ORR) in patients with high-risk resectable melanoma, compared to single-agent therapy with the PD-1 inhibitor.

Read the full story

Posted in Melanoma In The News, Information

Gut Bacteria and Anticancer Therapy — Chromatography Studies the Link

A new study has found that the type of bacteria in the gut of cancer patients is affected by the type of treatment.

Read the full story

Posted in Melanoma In The News, Information

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories